Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective

Anticancer Agents Med Chem. 2015;15(8):988-1011. doi: 10.2174/1871520615666150312100259.

Abstract

Overexpression of epidermal growth factor receptor (EGFR) is seen in a number of human tumors like prostate, colon, breast and ovarian. Their expression is correlated with vascularity and often difficult to diagnose. Though a number of active inhibitors and anticancer drugs against EGFR-tyrosine kinase are known, increase in resistance together with many side effects designate the need for new and improved treatments. Natural products and their analoges have significant contribution in the cancer drug discovery and development process. Therefore in the current review we mainly discuss design, synthesis and structural activity relationship of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / isolation & purification*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biological Products / chemistry*
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Catalytic Domain
  • Drug Discovery / methods
  • ErbB Receptors / antagonists & inhibitors*
  • Humans
  • Models, Molecular
  • Molecular Targeted Therapy
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / isolation & purification*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Biological Products
  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors